CVE:ACST

Acasti Pharma - ACST Stock Forecast, Price & News

C$0.92

+0.06 (+6.98%)

(As of 02/2/2023 05:20 PM ET)

Add

Compare

Today's Range: C$0.91
▼
C$0.92
50-Day Range: C$0.47
▼
C$1.12
52-Week Range: C$0.47
▼
C$1.66

Volume: 2,300 shs
Average Volume: 9,600 shs
Market Capitalization: C$41.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Acasti Pharma (CVE:ACST) Stock

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Stock News Headlines

January 13, 2023 | benzinga.com

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

November 15, 2022 | seekingalpha.com

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript

February 2, 2023 | Investing Trends (Ad)

The Biggest "Missing Ingredient" in the $7 Trillion EV Market

China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.

November 9, 2022 | it.tmcnet.com

Acasti Pharma to Present at Q4 Investor Summit

November 8, 2022 | tmcnet.com

Acasti Pharma to Report Second Quarter 2023 Financial

September 17, 2022 | theglobeandmail.com

Acasti Pharma: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (ACST)

September 14, 2022 | finance.yahoo.com

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

September 13, 2022 | it.tmcnet.com

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

February 2, 2023 | Investing Trends (Ad)

The Biggest "Missing Ingredient" in the $7 Trillion EV Market

July 27, 2022 | finance.yahoo.com

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

July 9, 2022 | finanznachrichten.de

Stock Day Media: Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast

July 7, 2022 | finance.yahoo.com

Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast

June 21, 2022 | seekingalpha.com

Acasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call Transcript

June 21, 2022 | seekingalpha.com

Acasti Pharma reports GAAP EPS of $0.27 for FY2022

May 12, 2022 | apnews.com

Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th

March 9, 2022 | finance.yahoo.com

Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

February 7, 2022 | finance.yahoo.com

Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call

December 22, 2021 | benzinga.com

Thinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma?

November 24, 2021 | finance.yahoo.com

Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd

November 4, 2021 | finance.yahoo.com

Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call

October 8, 2021 | proactiveinvestors.com

Acasti Pharma outlines key benefits of recent Grace Therapeutics acquisition

October 6, 2021 | finance.yahoo.com

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

September 29, 2021 | benzinga.com

Acasti Pharma Announces Initiation Of Pharmacokinetic Bridging Study For GTX-104

August 31, 2021 | msn.com

Why Shares of Acasti Pharma Slumped Tuesday

August 28, 2021 | benzinga.com

Acasti Says 8-For-1 Reverse Stock Split Will Be implemented To Help Regain Nasdaq Compliance

July 6, 2021 | ca.finance.yahoo.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Acasti Pharma Inc. Merger

July 3, 2021 | markets.businessinsider.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acasti Pharma, Inc. - ACST

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Company Calendar

Today: 2/02/2023
Next Earnings (Estimated): 2/13/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: CVE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: CVE:ACST
Previous Symbol: CVE:APO
CUSIP: N/A
CIK: N/A
Web: www.acastipharma.com
Phone: +1-450-6864555
Fax: N/A
Employees: 32
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.52
Current Ratio: 9.86
Quick Ratio: 9.41

Sales & Book Value

Annual Sales: C$115,000.00
Price / Sales: 356.90
Cash Flow: C$1.47 per share
Price / Cash Flow: 0.63
Book Value: C$2.25 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 44,613,000
Free Float: N/A
Market Cap: C$41.04 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Ms. Janelle D'Alvise (Age 68)
Pres, CEO, Corp. Sec. & Director
Comp: $620.16k

Dr. Pierre Lemieux M.D. (Age 58)
Ph.D., Co-Founder, COO & Chief Scientific Officer
Comp: $398.75k

Mr. Brian D. Ford CPA (Age 64)
CA, Chief Financial Officer
Comp: $340.84k

Dr. George Kottayil (Age 60)
Chief Operating Officer of US
Comp: $160.16k

Mr. Prashant Kohli
Chief Commercial Officer

Dr. Yves Lachance Ph.D.
VP of Quality & Compliance

Ms. Christine Pelletier
Sr. Director of HR

Key Competitors

View All Competitors

ACST Stock - Frequently Asked Questions

How have ACST shares performed in 2023?: Acasti Pharma's stock was trading at C$0.75 at the start of the year. Since then, ACST shares have increased by 22.7% and is now trading at C$0.92.
View the best growth stocks for 2023 here.
When is Acasti Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our ACST earnings forecast.
What other stocks do shareholders of Acasti Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), Aurora Cannabis (ACB), SCYNEXIS (SCYX), Block (SQ), Nokia Oyj (NOK), Axsome Therapeutics (AXSM), Blink Charging (BLNK), Inovio Pharmaceuticals (INO), Okta (OKTA) and Tesla (TSLA).

What is Acasti Pharma's stock symbol?: Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."
How do I buy shares of Acasti Pharma?: Shares of ACST stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Acasti Pharma's stock price today?: One share of ACST stock can currently be purchased for approximately C$0.92.
How much money does Acasti Pharma make?: Acasti Pharma (CVE:ACST) has a market capitalization of C$41.04 million and generates C$115,000.00 in revenue each year.
How can I contact Acasti Pharma?: Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The official website for the company is www.acastipharma.com. The company can be reached via phone at +1-450-6864555.

This page (CVE:ACST) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial